This startup develops advanced medical technologies focused on stimulating the body's natural regenerative processes to heal soft tissues. Their work aims to leverage the body's inherent capabilities for tissue repair and recovery.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with diabetes, peripheral artery disease (PAD), and other conditions often suffer from poor perfusion in their extremities, leading to tissue death, non-healing wounds, and increased risk of amputation. Current treatments often fail to adequately restore blood flow and promote tissue regeneration in these patients, resulting in high rates of amputation and mortality.
Solution
BioDynamik develops medical devices that leverage the body’s natural healing abilities to restore perfusion in affected limbs and promote limb preservation. Their XT3 System facilitates transverse tibial transport (TTT), a technique that stimulates angiogenesis and restores circulation in ischemic tissues. The TTT procedure involves creating a controlled osteotomy in the tibia, triggering an inflammatory response and mobilizing wound-healing cells to the affected area. This process enhances blood flow, promotes tissue repair, and reduces the risk of amputation in patients with chronic wounds and ischemic conditions.
Target Audience
The primary target audience includes vascular surgeons, podiatric surgeons, and plastic/dermatology surgeons treating patients with chronic wounds, diabetic foot ulcers, critical limb ischemia (CLI), and peripheral artery disease (PAD).
Features
- XT3 System designed to perform transverse bone transport in the tibia
- Controlled osteotomy to trigger an inflammatory response and hematoma formation
- Immunomodulation to shift the pro-inflammatory environment to promote wound repair
- Enhanced levels of growth factors (VEGF, bFGF, EGF, and PDGF) to support stem cell activation and angiogenesis
- Angiogenesis to restore microcirculation and enhance perfusion to ischemic tissues
- Actuating implants for distraction osteogenesis